MedoveX Corp. has closed an acquisition of Regenerative Medicine Solutions LLC, a biomedical services company that operates the Lung Health Institute.

As part of the transaction, Alpharetta, Ga.-based MedoveX issued 583,333 common shares and about 30,120 series C preferred shares to Regenerative Medicine. MedoveX also agreed to give Regenerative Medicine additional exchange shares and $350,000. Each series C preferred share in the transaction will be converted to 1,000 common shares of MedoveX.

Tampa, Fla.-based Regenerative Medicine manages all five clinics of the Lung Health Institute, a provider of cellular therapies to treat chronic obstructive pulmonary disease and other chronic lung disorders.